Fulminant hepatic failure following marijuana drug abuse: Molecular adsorbent recirculation system therapy

Swarnalatha, G; Pai, Shweta; Ram, R; Dakshinamurty, Kaligotla Venkata

doi:10.4103/0971-4065.116335

Cited by 8 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabis use is not known to promote hepatotoxicity. An unusual case of fulminant hepatic failure following cannabis abuse is described 78 . Some studies indicate that daily cannabis consumption may aggravate fibrosis in patients with pre‐existing hepatitis C, which was not the case here 79–81 .…”

Section: Discussionmentioning

confidence: 92%

Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)

Bouquet

Pain

Eiden

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims To describe the adverse events (AEs) of recreational cannabis use in France between 2012 and 2017. Methods AEs related to recreational cannabis use, alone or in combination with alcohol and/or tobacco reported to the French Addictovigilance Network were analysed (excluding cannabidiol and synthetic cannabinoids). Results Reporting of AEs tripled between 2012 (n = 179, 6.3%, 95% confidence interval [CI] = 5.4–7.2) and 2017 (n = 562, 10.1%, 95% CI = 9.3–10.9), reaching 2217 cases. They concerned mainly men (76.4%) and users aged between 18 and 34 years (18–25: 30.9%; 26–34: 26.3%, range: 12–84 years). Cannabis was mainly inhaled (71.6%) and exposure was most often chronic (64.2%). Many types of AEs were reported: psychiatric (51.2%), neurological (15.6%), cardiac (7.8%) and gastrointestinal (7.7%), including unexpected AEs (n = 34, 1.1%). The most common effect was dependence, ranging from 10.1% (95% CI = 7.9–12.3) to 20.3% (95% CI = 17.3–23.2) over the study period. Cannabinoid hyperemesis syndrome (n = 87, 2.8%) emerged from 2015. Deaths accounted for 0.2% of all AEs (4 men and 3 women aged on average 35 years). A chronic pattern of cannabis use was reported in 4 of them (intracranial hypertension in the context of lung cancer, suicide, cerebral haematoma, neonatal death with concomitant chronic alcohol use), while in the other cases the toxicological analysis identified cannabis use (ruptured aneurysm and unknown aetiology). Conclusion This study showed a multitude of AEs related to recreational cannabis use, including unexpected AEs and deaths. It highlights the problem of dependence and the emergence of cannabinoid hyperemesis syndrome.

show abstract

Section: Discussionmentioning

confidence: 92%

Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)

Bouquet

Pain

Eiden

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Artificial Liver Treatment, When and Which One?

Mitzner¹,

Grabow²,

Klammt³

2016

Contemporary Liver Transplantation

View full text Add to dashboard Cite

Patients awaiting liver transplantation often are in critical condition with multi-organ failure accompanying the underlying liver disease. Stabilization and safe bridging of the patient to transplantation is a major indication for liver support methods. Various extracorporeal technologies have been tested clinically since the late 1950s. Currently, methods are divided into artificial, or nonbiological, systems based mainly on filtration and adsorption techniques and biological methods employing liver cells, typically of human, sometimes of animal origin. Examples of currently used liver support methods are the molecular adsorbent recirculating system (MARS) as an artificial system and the extracorporeal liver assist device (ELAD) as a biological liver-cell bioreactor. However, a considerable number of other approaches have been studied before or are currently under investigation. As of today, the best clinical experience exists for the MARS system. Liver support treatment should be considered early in the course of liver failure. Stabilization of various organ functions including circulatory, hepatic, and renal function, improvement of hepatic encephalopathy, and reduction of elevated intracranial pressure were observed in clinical studies. Modern extracorporeal liver support methods are safe to perform and a valuable addition to the therapeutic armamentarium of liver failure care.

show abstract

Artificial Liver Treatment, When and Which One?

Mitzner¹,

Grabow²,

Klammt³

2016

Contemporary Liver Transplantation

View full text Add to dashboard Cite

Patients awaiting liver transplantation often are in critical condition with multi-organ failure accompanying the underlying liver disease. Stabilization and safe bridging of the patient to transplantation is a major indication for liver support methods. Various extracorporeal technologies have been tested clinically since the late 1950s. Currently, methods are divided into artificial, or nonbiological, systems based mainly on filtration and adsorption techniques and biological methods employing liver cells, typically of human, sometimes of animal origin. Examples of currently used liver support methods are the molecular adsorbent recirculating system (MARS) as an artificial system and the extracorporeal liver assist device (ELAD) as a biological liver-cell bioreactor. However, a considerable number of other approaches have been studied before or are currently under investigation. As of today, the best clinical experience exists for the MARS system.Liver support treatment should be considered early in the course of liver failure. Stabilization of various organ functions including circulatory, hepatic, and renal function, improvement of hepatic encephalopathy, and reduction of elevated intracranial pressure were observed in clinical studies. Modern extracorporeal liver support methods are safe to perform and a valuable addition to the therapeutic armamentarium of liver failure care.

show abstract

Fulminant hepatic failure following marijuana drug abuse: Molecular adsorbent recirculation system therapy

Cited by 8 publications

References 10 publications

Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)

Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)

Artificial Liver Treatment, When and Which One?

Artificial Liver Treatment, When and Which One?

Contact Info

Product

Resources

About